A clinical-stage biopharmaceutical company focused on developing oncological therapies to improve patient outcomes.

Carrick Therapeutics

Carrick Therapeutics is pioneering a portfolio of unique, first in class, cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient’s tumour.
Targeting the molecular pathways that drive the most aggressive and resistant forms of cancer will transform the way that cancer is treated and have a major impact on the lives of cancer patients. By linking a network of clinicians and scientists in internationally leading research institutes and hospitals, Carrick will streamline the introduction of these ground-breaking cancer therapies into the clinic, thus serving cancer patients around the world.

Woodford Investment Management

Lightstone Ventures

Cambridge Innovation Capital

Evotec

University of Cambridge Enterprise

ARCH Venture Partners

Google Ventures

Pfizer

Revelation Partners

Rosetta Capital

Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer

https://lnkd.in/eTajEtpM

Delighted to announce a First Patient Dosed in our Phase 2b Clinical Trial of Samuraciclib in Combination with Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer. 

https://lnkd.in/e8deVH6g

Great interview on Oncology Tube with our CMO Stuart McIntosh talking about our ongoing Phase 2 study SUMIT-ELA, combining samuraciclib and elacestrant in patients with CDK4/6i resistant HR+,HER2- metastatic breast cancer in collaboration with Menarini. 

https://lnkd.in/ezt5ZqWW

Delighted to announce US FDA clearance of our IND for CT7439, a First In Class Inhibitor of CDK12/13. Carrick's second therapeutic candidate which further strengthens our oncology pipeline.
https://lnkd.in/e7WuT_9v

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Jul 27, 2024 2:22 AM	c335cbd5
public peers	general	Jul 26, 2024 4:13 AM	169cf2d7
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 26, 2024 2:15 PM	21a8f1c9
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Jul 26, 2024 4:13 AM	6fcc8fa8
translate crunchbase fundingrounds	general
peers	general	Jul 26, 2024 4:13 AM	00fa3d9d
news basic	general	Jul 26, 2024 4:13 AM	bdb0549d
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:CARRICKTHERAPEUTICS

Carrick Therapeutics